Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Affiliations

Sha-Sha Wang: Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
Fang Wang: Department of Internal Medicine, OASIS International Hospital, Beijing, China
Zhen Zeng: Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
Fang Gao: Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
Huan-Huan Liu: Department of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, China
Hui-Na Wang: Department of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, China
Yi Hu: Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
Hai-Feng Qin: Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China

Abstract

No abstracts available.

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/